Alpha1-antitrypsin exists in over 70 biochemical genetic variants -the protease inhibitor system (Pi).' Epidemiologically the most significant Pi types are M, S, and Z. Homozygotes deficient of the Z type have only 10- 20% of the normal serum concentration of the inhibitor and have an increased risk of developing pulmonary emphysema, with cigarette smoking being the most important risk factor.
Most studies of the effect of a,-antitrypsin deficiency on lung function have shown the development of early emphysema, but the patients in these studies were highly selected. A few studies have compared severely disabled PiZ patients with their relatives and found a wide range of lung function impairment, suggesting that factors other than cigarette smoking contribute to emphysema and early death.24
Calculation of survival time in patients homozygous for type PiZ indicates that they have a poor prognosis, but such estimates are based on hospital populations already suffering from respiratory symptoms at the time of diagnosis.5 Calculations based on population frequencies of the Z gene suggest that about 90% of these subjects are not accounted for in such surveys.
To calculate the true mortality rate of all type PiZ homozygotic subjects large population screens must be performed and the affected subjects followed through their whole life span -a task that started in Sweden in 1972. 6 The aim of this study was to estimate the survival time of patients with aX-antitrypsin deficiency and to compare index cases with non-index cases. By including a large number of non-index cases in the analysis selection bias was reduced. The demographic data of the study population are shown in table 2. Men and women are equally represented, and the 252 index cases and 145 non-index cases differed significantly in smoking habits and follow up time. Of the index cases 8% had never smoked compared with 33% of the non-index cases. The nonindex cases had been followed for longer than the index cases with a median follow up time of 7-4 years compared with 4-7 years. There was no significant difference in age at diagnosis between the index and non-index cases.
Methods
The overall median survival time was 54-2 years (95% confidence limits 502 to 58-3), with no significant difference between men and women. Figure 1 summarises the survival curves of index and non-index cases. There was a highly significant difference in survival between the two groups with a median survival of 49-4 years (95% CI 42-4 to 53 6) for the index group and 69-3 years (95% CI 65-9 to 82 1) for the non-index group (p<0-0001), both being significantly less than the survival of the normal Danish population.
The survival of smokers was significantly less than for non-smokers (p<0.0001) with a median survival time of 518 years (95% CI 47-2 to 56-1) for smokers and 66-8 years (95% CI 65-3 to 75-1) for never smokers (fig 2) . The survival time of the never smokers was significantly less than for the normal Danish population.
To analyse the interaction between mode of identification and smoking history the survival times of smokers and never smokers were compared for index and non-index cases This study is not devoid of selection bias vival time of smokers and never smokers was because it is possible that in some families with not significantly different, but for non-index a,-antitrypsin deficiency even smokers do not cases the survival of smokers was less than that develop emphysema and thus will never be of never smokers (p < 0.05). For non-index diagnosed. Selection bias has been overcome cases the survival time of never smokers was to some extent by comparing the survival of not significantly different from that of the 252 patients with a,-antitrypsin deficiency normal Danish population.
identified because of lung disease with 145 A quantitative analysis of smoking history identified through family studies. A large difwas performed using the Cox proportional ference in life expectancy was found even hazards regression model with time dependent when we controlled for smoking history. The variables.'0 Index cases were analysed against two groups differed significantly with respect non-index cases, with sex and the total lifetime to follow up time and smoking history. The tobacco consumption in terms of pack-years age at diagnosis was higher for the index cases, being entered as covariates. Index cases had a but not significantly. The differences in age at relative risk of 3-47 (95% CI 2 02 to 5 98) diagnosis and follow up time have been taken compared with non-index cases. Neither sex into account in our calculations by using the nor the total tobacco consumption influenced actuarial life table method and cannot explain the excess mortality of index cases. When the the variability in survival.
non-index cases only were analysed the excess When the patients were stratified for mode mortality of smokers applied to patients with a of identification and the survival of smokers smoking history of more than 10 pack years and never smokers was analysed, smoking did with a relative risk of 3-1 (95% CI 1*01 to 9-7). not seem to be the main risk factor. Among index cases there was no significant difference in survival time between smokers and never Discussion smokers; this may be a result of the limited Previous studies on the natural history of number of never smokers in the study. The a,i-antitrypsin deficiency indicate that it is a total lifetime tobacco consumption in terms of serious disorder with considerably reduced life pack years did not influence survival when included in the Cox regression model. In contrast to previous studies our population contained an equal number of men and women with no sex specific difference in survival rate. The male predominance characteristic of other studies is probably a selection problem caused by the higher proportion of male smokers in the general population.4 1618 In previous studies the life expectancy of patients with -antitrypsin deficiency was estimated to be about 40-50 years. We found an overall median life expectancy of 54 6 years, but with large differences between index and non-index cases. The true life expectancy is probably somewhere in between the two groups and can be estimated more accurately when more non-index cases are included in the calculations and the follow up time is longer.
reference to non-index cases.
1-antitrypsin deficiency with special
Survival of patients with severe alpha Somewhat dated chapters on the usefulness of peak flow meter readings and compliance with medication are followed by more interesting studies on patient self-management, and the quality of life in patients with COPD.
The final chapter provides a general discussion on the studies reported in the book, and concludes that there is much room for improvement in the general practice care of asthma and COPD -a message of equal relevance to the UK. Four developments in quality of care are highlighted: the emergence of guidelines and quality standards for management; the important role ofpractice nurses in patient education; and the potential roles of patient self-management plans and patient satisfaction surveys in care of asthma and COPD. As in the UK, all of these developments are being espoused enthusiastically, although we await convincing evidence of their effectiveness.
The book is a useful addition for general practitioners with a special interest in the subject, but not one which offers important new messages for the true generalist for whom a quick scan of the five page summary chapter will be sufficient. - 
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The chest radiograph in Survival of patients with cysuc norosis
In the paper entitled "The chest radiograph in cystic fibrosis: a new scoring system compared with the Chrispin-Norman and Brasfield scores" by S P Conway et al which appeared on pages 860-862 of the September issue a line of text was inadvertently omitted. The last paragraph on page 860 should read: "The Northern score is derived by dividing each lung into an upper and lower zone by drawing a horizontal line outwards from the middle 
